Shares of Humacyte, Inc. (HUMA) soared over 10% in pre-market trading on Thursday, following positive analyst ratings from two Wall Street firms.
TD Cowen analyst Josh Jennings reiterated a "Buy" rating on HUMA and set a price target of $10.00. Meanwhile, Piper Sandler analyst Allison Bratzel maintained a "Hold" rating but raised the firm's price target to $6.00.
The analyst ratings suggest a positive sentiment towards Humacyte's prospects, driving investor optimism and contributing to the pre-market surge in the company's stock price.
免责声明：投资有风险，本文并非投资建议，以上内容不应被视为任何金融产品的购买或出售要约、建议或邀请，作者或其他用户的任何相关讨论、评论或帖子也不应被视为此类内容。本文仅供一般参考，不考虑您的个人投资目标、财务状况或需求。TTM对信息的准确性和完整性不承担任何责任或保证，投资者应自行研究并在投资前寻求专业建议。